Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Tumors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07302100
What this trial is testing

Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
University Hospital, Strasbourg, France 100
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Ended earlyNCT02078843
What this trial is testing

Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Insel Gruppe AG, University Hospital Bern 54
Not applicableStudy completedNCT05255133
What this trial is testing

Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment

Who this might be right for
Neuroendocrine Tumors
Universiteit Antwerpen 22
Not applicableActive Not RecruitingNCT04804371
What this trial is testing

Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 40
Not applicableStudy completedNCT03012789
What this trial is testing

Surgical Intervention and the NETest

Who this might be right for
Neuroendocrine TumorGastroenteropancreatic
Wren Laboratories LLC 30
Testing effectiveness (Phase 2)UnknownNCT02687958
What this trial is testing

Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin

Who this might be right for
Neuroendocrine Carcinoma
Gruppo Oncologico Italiano di Ricerca Clinica 30
Testing effectiveness (Phase 2)Study completedNCT02250885
What this trial is testing

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Who this might be right for
Carcinoma, Neuroendocrine
Gabrail Cancer Center Research 14
Testing effectiveness (Phase 2)Study completedNCT03980925
What this trial is testing

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Who this might be right for
Neuroendocrine TumorsNeuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine Tumor
Grupo Espanol de Tumores Neuroendocrinos 37
Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Not applicableStudy completedNCT02788565
What this trial is testing

Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumours
Ipsen 156
Testing effectiveness (Phase 2)Ended earlyNCT03670030
What this trial is testing

TestABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System

Who this might be right for
Neuroendocrine Tumors
Robert Ramirez 5
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more
Perspective Therapeutics 300
Post-approval studies (Phase 4)Looking for participantsNCT06016855
What this trial is testing

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Digestive System Neuroendocrine Tumor G1Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Neoplasm+3 more
Vanderbilt-Ingram Cancer Center 6
Testing effectiveness (Phase 2)Looking for participantsNCT05652686
What this trial is testing

Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

Who this might be right for
Small Cell Lung Cancer (SCLC)Large Cell Neuroendocrine Cancer (LCNEC)Neuroendocrine Prostate Cancer (NEPC)+3 more
Phanes Therapeutics 203
Testing effectiveness (Phase 2)Ended earlyNCT03042780
What this trial is testing

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more
H. Lee Moffitt Cancer Center and Research Institute 2
Testing effectiveness (Phase 2)Looking for participantsNCT06840821
What this trial is testing

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Who this might be right for
Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd 156
Testing effectiveness (Phase 2)UnknownNCT03457844
What this trial is testing

Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor G3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 60
Not applicableLooking for participantsNCT07635316
What this trial is testing

Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 4,023
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Next Page